Molecular basis of CLL.
paper
Cited
Public
- Authors
- Pekarsky, Yuri; Zanesi, Nicola; Croce, Carlo M
- Year
- 2010
- Journal
- Seminars in cancer biology
- PMID
- 20863894
- DOI
- 10.1016/j.semcancer.2010.09.003
- PMCID
- PMC2997849
B-cell chronic lymphocytic leukemia (CLL), the most common leukemia in the Western world, results from an expansion of a rare population of CD5+ mature B-lymphocytes. CLL occurs in two forms, aggressive and indolent. For the most part indolent CLL is characterized by low ZAP-70 expression and mutated IgH V(H); aggressive CLL shows high ZAP-70 expression and unmutated IgH V(H). Although clinical features and genomic abnormalities in CLL have been studied extensively, molecular mechanisms underlying disease development are still emerging. In the last few years, several important insights were reported in this area. MiR-15/16 targeting BCL2 and MCL1 and DLEU7 targeting TNF pathway were proposed as tumor suppressors at 13q14, a commonly deleted region in indolent CLL. Molecular details of how activation of TCL1, a critical oncogene in aggressive CLL, results in the initiation of this malignancy were clarified. Importance of these pathways was supported by investigations of several mouse models of CLL. Here, we present what has been learned from these new pathways, discuss mouse CLL models and how these mouse models recapitulate the molecular mechanisms of this common leukemia.
No figures extracted from this document.
| # | Section | Preview |
|---|---|---|
| 40 | Introduction β Mouse models of CLL β APRIL driven mouse model of CLL | NF-kB is a downstream target of TRAFs (Figure 1). Hence, it is possible that activation of NF-kBβ¦ |
| 41 | Introduction β Mouse models of CLL β APRIL driven mouse model of CLL | milder phenotype than TCL1 or TRAF2DN/BCL2 transgenic animals. APRIL mice showed only mild expansionβ¦ |
| 42 | Conclusions | In the last few years, several important studies uncovering molecular mechanisms of CLL pathogenesis⦠|
| 43 | Conclusions | BCL2/TRAF2DN transgenic mouse model represents a very interesting parallel and confirmation for the⦠|
β Prev
41β44 of 44
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Detectable clonal mosaicism and its relationship to aging and cancer. | 2012 | 22561519 |
| Detectable clonal mosaicism from birth to old age and its relationship to cancer. | 2012 | 22561516 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Lacrimal Sac Chronic Lymphocytic Leukemia: A Review of Clinical Features, Investigations, and Management. | Reigler O et al. | β | 2025 | β |
| Advances in epigenetic alterations of chronic lymphocytic leukemia: from pathogenesis to treatment. | Zhang X et al. | β | 2024 | β |
| CLLU1 as an emerging biomarker in chronic lymphoid leukemia. | Rong C et al. | β | 2024 | β |
| Emerging roles of circRNAs in leukemia and the clinical prospects: An update. | Deng W et al. | β | 2023 | β |
| Expression signature of human endogenous retroviruses in chronic lymphocytic leukemia. | Ferlita A et al. | β | 2023 | β |
| The proto-oncogene TCL1A deregulates cell cycle andΒ genomic stability in CLL. | Stachelscheid J et al. | β | 2023 | β |
| The Research Advances of Aptamers in Hematologic Malignancies. | Liao Y et al. | β | 2023 | β |
| Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. | Jelloul FZ et al. | β | 2022 | β |
| Polysome-CAGE of TCL1-driven chronic lymphocytic leukemia revealed multiple N-terminally altered epigenetic regulators and a translation stress signature | Ogran A et al. | β | 2022 | β |
| Polysome-CAGE of TCL1-driven chronic lymphocytic leukemia revealed multiple N-terminally altered epigenetic regulators and a translation stress signature. | Ogran A et al. | β | 2022 | β |
| Alterations in The Plasma Expression of mir-15b, mir-195 and the Tumor-Suppressor Gene DLEU7 in Patients with B-Cell Chronic Lymphocytic Leukemia. | Bagheri M et al. | β | 2021 | β |
| Non-Coding RNAs: The "Dark Side Matter" of the CLL Universe. | Lingua MF et al. | β | 2021 | β |
| The Modes of Dysregulation of the Proto-Oncogene T-Cell Leukemia/Lymphoma 1A. | Stachelscheid J et al. | β | 2021 | β |
| Aspartic Aminopeptidase Is a Novel Biomarker of Aggressive Chronic Lymphocytic Leukemia. | Kakodkar P et al. | β | 2020 | β |
| Molecular modelling of epitopes recognized by neoplastic B lymphocytes in Chronic Lymphocytic Leukemia. | Lupia A et al. | β | 2020 | β |
| Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia. | Pepe F et al. | β | 2020 | β |
| Venetoclax in the Treatment of Chronic Lymphocytic Leukemia: Evidence, Expectations, and Future Prospects. | Tariq S et al. | β | 2020 | β |
| Cell death pathologies: targeting death pathways and the immune system for cancer therapy. | Pentimalli F et al. | β | 2019 | β |
| Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance. | Pramil E et al. | β | 2019 | β |
| Aging and the rise of somatic cancer-associated mutations in normal tissues. | Risques RA et al. | β | 2018 | β |
| Chemotactic Cues for NOTCH1-Dependent Leukemia. | Piovan E et al. | β | 2018 | β |
| Microenvironmental stromal cells abrogate NF-ΞΊB inhibitor-induced apoptosis in chronic lymphocytic leukemia. | Simon-Gabriel CP et al. | β | 2018 | β |
| Common nonmutational <i>NOTCH1</i> activation in chronic lymphocytic leukemia. | Fabbri G et al. | β | 2017 | β |
| Exonal switch down-regulates the expression of CD5 on blasts of acute T cell leukaemia. | Rai AK et al. | β | 2017 | β |
| Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer. | Pekarsky Y et al. | β | 2016 | β |
| Expression and regulation of CacyBP/SIP in chronic lymphocytic leukemia cell balances of cell proliferation with apoptosis. | Fu C et al. | β | 2016 | β |
| Expression and regulation of COP1 in chronic lymphocytic leukemia cells for promotion of cell proliferation and tumorigenicity. | Fu C et al. | β | 2016 | β |
| Plumbagin reduces chronic lymphocytic leukemia cell survival by downregulation of Bcl-2 but upregulation of the Bax protein level. | Fu C et al. | β | 2016 | β |
| The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia. | Itchaki G et al. | β | 2016 | β |
| CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCΞ³1 activation: evidence from mice and humans. | Martinez-Torres AC et al. | β | 2015 | β |
| Clinical relevance of vascular endothelial growth factor type A (VEGFA) and VEGF receptor type 2 (VEGFR2) gene polymorphism in chronic lymphocytic leukemia. | GΓ³ra-Tybor J et al. | β | 2015 | β |
| Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis. | Shahjahani M et al. | β | 2015 | β |
| Molecular pathogenesis of CLL and its evolution. | RodrΓguez D et al. | β | 2015 | β |
| Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia. | RodrΓguez D et al. | β | 2015 | β |
| Non-coding recurrent mutations in chronic lymphocytic leukaemia. | Puente XS et al. | β | 2015 | β |
| PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model. | Motiwala T et al. | β | 2015 | β |
| TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. | Balatti V et al. | β | 2015 | β |
| The long journey of TCL1 transgenic mice: lessons learned in the last 15 years. | Pekarsky Y et al. | β | 2015 | β |
| Acidosis Sensing Receptor GPR65 Correlates with Anti-Apoptotic Bcl-2 Family Member Expression in CLL Cells: Potential Implications for the CLL Microenvironment. | Rosko AE et al. | β | 2014 | β |
| The role of miR-29 family members in malignant hematopoiesis. | Kollinerova S et al. | β | 2014 | β |
| Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene. | Acunzo M et al. | β | 2014 | β |
| A protein disulfide isomerase/thioredoxin-1 complex is physically attached to exofacial membrane tumor necrosis factor receptors: overexpression in chronic lymphocytic leukemia cells. | SΓΆderberg A et al. | β | 2013 | β |
| A Sleeping Beauty screen reveals NF-kB activation in CLL mouse model. | Zanesi N et al. | β | 2013 | β |
| Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. | Hoeller S et al. | β | 2013 | β |
| POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. | Ramsay AJ et al. | β | 2013 | β |
| Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. | Pouliot LM et al. | β | 2012 | β |
| Congenital B cell lymphocytosis explained by novel germline CARD11 mutations. | Snow AL et al. | β | 2012 | β |
| Detectable clonal mosaicism and its relationship to aging and cancer. | Jacobs KB et al. | β | 2012 | β |
| Detectable clonal mosaicism from birth to old age and its relationship to cancer. | Laurie CC et al. | β | 2012 | β |
| Genome-wide association study of lung function decline in adults with and without asthma. | Imboden M et al. | β | 2012 | β |
| Lipoprotein lipase: a new prognostic factor in chronic lymphocytic leukaemia. | Hartman ML et al. | β | 2012 | β |
| Epigenomics of leukemia: from mechanisms to therapeutic applications. | Florean C et al. | β | 2011 | β |
| Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation. | Spagnuolo C et al. | β | 2011 | β |